Author:
Smaletz O.,Galsky M.,Scher H.I.,DeLaCruz A.,Slovin S.F.,Morris M.J.,Solit D.B.,Davar U.,Schwartz L.,Kelly W.K.
Reference24 articles.
1. Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer;Dexeus;Cancer Treat Rep,1985
2. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results;Picus;Semin Oncol,1999
3. Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group;Roth;Cancer,1993
4. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer;Seidman;J Urol,1992
5. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780;Savarese;Cancer and Leukemia Group B. J Clin Oncol,2001
Cited by
63 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献